CLBT
Cellebrite DI
11.20$
+1.2%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +11.7% | -0.7% | +5.2% | +13.1% | +9.7% | +2.8% | +10.9% | +6.0% | +12.5% | +1.4% | +4.4% | |
| – | +12.8% | -11.6% | +11.2% | +20.9% | +13.2% | -7.8% | +15.8% | +10.3% | -13.8% | -7.1% | +9.0% | |
| – | +38.3% | -35.4% | -12.6% | +27.5% | +40.6% | -52.8% | +98.1% | +57.0% | -55.8% | +7.4% | +5.7% | |
| – | +14.9% | -8.7% | +10.4% | +21.4% | +20.6% | -8.4% | +15.3% | +11.3% | -16.9% | -1.8% | +3.1% | |
| – | +11.1% | -20.2% | +14.7% | +32.6% | -12.1% | -1.5% | +14.8% | +11.9% | +0.7% | -30.7% | +52.3% | |
| – | -11.3% | -6.9% | -5.1% | +10.7% | -8.1% | +0.3% | +6.3% | -9.3% | -12.1% | -1.0% | +11.4% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.0% | +0.0% | +0.0% | +7.0% | +0.0% | +0.0% | +0.0% | +0.0% | +316.4% | +0.0% | +0.0% | |
| – | -5.0% | -1.7% | -5.9% | +15.4% | -0.1% | -3.4% | -6.2% | -4.2% | +730.7% | +57.1% | -4.7% | |
| – | +13.6% | +11.5% | +7.4% | -44.5% | +7.1% | -2.3% | +9.4% | +2.0% | +17.6% | -2.8% | +3.3% | |
| – | +11.9% | -7.6% | +1.1% | +15.0% | +8.3% | -2.6% | +7.7% | +2.2% | +16.6% | -5.3% | +4.0% | |
| – | +5.8% | -2.7% | -6.6% | -1.0% | -7.9% | +2.1% | +0.6% | -14.6% | +10.4% | +15.0% | +24.8% | |
| – | +3.7% | -14.9% | -7.6% | +11.8% | +52.2% | -7.8% | +3.7% | +5.2% | +51.2% | -35.4% | +66.7% | |
| – | -9.8% | -178.1% | – | – | +12.6% | +8.2% | +12.4% | +9.6% | +8.2% | +5.4% | +5.4% | |
| – | -11.0% | -60.4% | -50.9% | -902.0% | – | – | – | – | – | – | – | |
| – | -4.9% | +1.2% | +1.1% | +4.9% | +18.5% | +0.8% | -0.1% | +0.3% | +0.7% | +0.2% | +0.3% |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.